# Sutro Biopharma Announces Participation at the 16th World ADC London Summit
Canonical URL: https://biopharmsignal.com/news/STRO/sutro-biopharma-announces-participation-at-the-16th-world-adc-london-summit-c229d910
Ticker: STRO
Company: Sutro Biopharma
Source: Sutro Biopharma
Published: 2026-02-23 13:30 EST
## Summary

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology...

## Article Body
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 16th World ADC London Summit, taking place in London, UK, February 23-26, 2026.

Plenary/Panel Discussion Details:

Panel Discussion: ADC Licensing, Partnering & Investment Session Sutro Participant: Hans-Peter Gerber, Ph.D.

Date/Time: February 23, 2026, 3:00PM GMT

Panel Discussion: Evaluating the Cutting-Edge Innovation & Performance Driving ADC Differentiation & Progression Earlier Line Patient Therapies Sutro Participant: Hans-Peter Gerber, Ph.D.

Date/Time: February 24, 2026, 7:45AM GMT

Spotlighting Efficacy & Safety Profiles of Dual Payload ADCs Featuring Novel Linker Payloads to Overcome Resistance Mechanisms Presenter: Hans-Peter Gerber, Ph.D.

Date/Time: February 25, 2026, 9:00AM GMT

Following the event, the content from the plenary session will be made available in the Scientific Publications section of Sutro Biopharma’s website at www.sutrobio.com .

About Sutro Biopharma Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.

For more information, follow Sutro on social media @Sutrobio or visit www.sutrobio.com .

Investor Contact Emily White Sutro Biopharma (650) 823-7681 ewhite@sutrobio.com

Media Contact Amy Bonanno Lyra Strategic Advisory abonanno@lyraadvisory.com
## Recent Company News
- 2026-05-14 20:05 EST — [Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights](https://biopharmsignal.com/news/STRO/sutro-biopharma-reports-first-quarter-2026-financial-results-and-business-highli-43d18eb3) — Source: Sutro Biopharma
- 2026-04-19 23:45 EST — [Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026](https://biopharmsignal.com/news/STRO/sutro-biopharma-presents-promising-preclinical-data-across-its-pipeline-of-next--bdf8f4ce) — Source: Sutro Biopharma
- 2026-03-23 20:05 EST — [Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights](https://biopharmsignal.com/news/STRO/sutro-biopharma-reports-full-year-2025-financial-results-and-business-highlights-c81ab4c5) — Source: Sutro Biopharma
- 2026-02-25 13:30 EST — [Sutro Biopharma to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/STRO/sutro-biopharma-to-participate-in-upcoming-investor-conferences-5470cd63) — Source: Sutro Biopharma
- 2026-02-23 13:30 EST — [Sutro Biopharma Announces Participation at the 16th World ADC London Summit](https://biopharmsignal.com/news/STRO/sutro-biopharma-announces-participation-at-the-16th-world-adc-london-summit-c229d910) — Source: Sutro Biopharma
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)